Orthocell Posts Record U.S. Remplir Sales in October 2026
Australian medical device maker Orthocell recorded its strongest U.S. monthly sales of its Remplir nerve wrap since the product launched.
Orthocell Ltd, the Australian medical device company behind the Remplir collagen nerve wrap, reported its highest single-month U.S. sales total since the product's commercial launch, logging 92 units sold in October 2026, according to the company.
Remplir is an FDA-cleared device engineered to support the repair and protection of peripheral nerves. Designed and manufactured in Australia, the collagen-based wrap is positioned by the company as an emerging category leader in key international markets where peripheral nerve repair procedures are performed.
Read more EFICYENT to Join Global Fintech Leaders at Singapore FinTech Festival 2026 →
The October milestone signals growing clinical adoption in the United States, the world's largest medical device market. Strong monthly sales figures for a relatively new surgical product can reflect expanding surgeon awareness, repeat purchasing by existing accounts, or the addition of new hospital and ambulatory surgery center customers — factors the company did not detail in its release but which typically drive such gains.
Orthocell's Remplir competes in the peripheral nerve repair segment, a niche but expanding area of orthopedic and reconstructive surgery driven by trauma cases, tumor resections, and repetitive-stress injuries. FDA clearance remains a critical commercial gating factor for devices in this category, and Orthocell has already cleared that hurdle for the U.S. market.
Continue reading at All Financial Services & Investing.